Faria Capital Management
Biotech, small-cap, micro-cap, long/short equity

5 Reasons Why ADMA Biologics Is Worth A Look

One of my boys has been hospitalized twice in the last 18 months for a respiratory syncytial virus (RSV) infection. For most people, RSV is considered a common cold, but for people with immunodeficiencies or compromised pulmonary function, it can be deadly. While doing my research on the virus and potential ways to protect against it (there is currently no approved vaccine), I came across an interesting little company called ADMA Biologics (NASDAQ:ADMA). The company is small, illiquid, and not on a lot of radar screens, but there are quite a few reasons to take a closer look (ranked from most significant to least):

1) ADMA's lead product, RI-002, is an improved intravenous immunoglobulin (IVIG) product with an...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details